Distinguished in Non-Small Cell Lung Cancer (NCSLC)
Check Dr. Jianjun R. Zhang's experience treating your condition:
About Dr. Jianjun R. Zhang

Jianjun Zhang is an Oncologist in Houston, Texas. Zhang has been practicing medicine for over 25 years and is rated as a Distinguished expert by MediFind in the treatment of Non-Small Cell Lung Cancer (NCSLC). He is also highly rated in 20 other conditions, according to our data. His top areas of expertise are Lung Cancer, EGFR Positive Lung Cancer, Squamous Cell Lung Carcinoma, Endoscopy, and Gallbladder Removal. He is licensed to treat patients in Texas. Zhang is currently accepting new patients.

His clinical research consists of co-authoring 443 peer reviewed articles and participating in 4 clinical trials in the past 15 years. In particular, he has co-authored 72 articles and participated in 3 clinical trials in the study of Non-Small Cell Lung Cancer (NCSLC).


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Jianjun R. Zhang it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
1515 Holcombe Blvd, Houston, TX 77030
Background & Education
Graduate Institution
Other, 1997
Internal Medicine in TX
Hospital Affiliations
University Of Texas MD Anderson Cancer Center
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Single Arm Phase II Trial Using Canakinumab for the Prevention of Lung Cancer (Can-Prevent-Lung)
Randomized Phase II of Immunotherapy With Pembrolizumab for the Prevention of Lung Cancer (IMPRINT-Lung)
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
View 2 Less Clinical Trial -

440 Total Publications

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors